Emergent BioSolutions Awarded Over $250 Million in Contract Modifications for Critical Medical Countermeasure Products
Emergent BioSolutions Inc. secures over $250 million in contract modifications from the U.S. Department of Health and Human Services for critical medical countermeasure products, including anthrax and smallpox vaccines. The contracts affirm Emergent as a trusted biodefense partner.
Moderna Secures US Government Funding for Bird Flu Vaccine Development
Moderna secures US government funding to develop a vaccine for bird flu amid rising animal infections. With expertise in vaccine development, Moderna is a key player in combatting the virus. The funding will expedite research efforts to bring a vaccine to market, addressing the urgent public health concern of a potential bird flu outbreak.
U.S. Department of Health and Human Services Releases National Public Health Strategy to Prevent and Control Vector-Borne Diseases
The U.S. Department of Health and Human Services has released the National Public Health Strategy to Prevent and Control Vector-Borne Diseases in People (VBD National Strategy), marking a significant step in combating the growing threat of diseases spread by vectors such as mosquitoes, ticks, fleas, and lice. The strategy, developed by 17 federal departments and agencies, is a result of a four-year process initiated by the 2019 Kay Hagan Tick Act. This interagency plan aims to address the challenges related to vector-borne diseases and outlines federal priorities to detect, prevent, respond to, and control these diseases and conditions in the United States.